All In Biotech

Drug Trial Radar · NCT07541287

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 19, 2026

Primary completion

Jan 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Jade Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Conditions

  • IgA Nephropathy

Interventions

  • JADE101Drug

    JADE101 is supplied as sterile solution to be administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (safety and tolerability)Time frame: Day 1 through 100 weeks

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Jade Clinical Site

    Chula Vista, California · Recruiting

  • Jade Clinical Site

    Arvada, Colorado · Recruiting

  • Jade Clinical Site

    Denver, Colorado · Recruiting

  • Jade Clinical Site

    Orlando, Florida · Recruiting

  • Jade Clinical Site

    Pembroke Pines, Florida · Recruiting

  • Jade Clinical Site

    Houston, Texas · Recruiting

  • Jade Clinical Site

    Concord, New South Wales, Australia · Recruiting

  • Jade Clinical Site

    Liverpool, New South Wales, Australia · Recruiting

  • Jade Clinical Site

    Parkville, Victoria, Australia · Recruiting

  • Jade Clinical Site

    Christchurch, New Zealand · Recruiting

  • Jade Clinical Site

    Anyang-si, South Korea · Recruiting

  • Jade Clinical Site

    Seongnam-si, South Korea · Recruiting

  • Jade Clinical Site

    Seoul, South Korea · Recruiting

  • Jade Clinical Site

    Seoul, South Korea · Recruiting

  • Jade Clinical Site

    Seoul, South Korea · Recruiting

  • Jade Clinical Site

    Suwon, South Korea · Recruiting

  • Jade Clinical Site

    Kaohsiung City, Kaohsiung, Taiwan · Recruiting

  • Jade Clinical Site

    Taichung, Taichung, Taiwan · Recruiting

  • Jade Clinical Site

    New Taipei City, Taipei, Taiwan · Recruiting

  • Jade Clinical Site

    Taipei, Taipei, Taiwan · Recruiting

  • Jade Clinical Site

    Taipei City, Taipei, Taiwan · Recruiting

  • Jade Clinical Site

    Taiyuan, Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.